U.S.-headquartered Gemelli Biotech Corp, which focuses on precision diagnostics for gastrointestinal (GI) diseases, has completed a $19 million series A finance round.
Blue Ox Healthcare Partners, a private equity firm providing growth capital to companies targeting precision health and value-based care, led the investment round, joined by founding investor Cedars-Sinai, along with Carolina Angel Network, CerraCap Ventures, and several family offices.